Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 10/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4062469 | 0.83 | USP30 (0.63) | ADORA1USP30ADORA3ADORA2AADORA2B | |
| SCHEMBL13608179 | 0.82 | GRIN1 (0.48) | ADORA1GRIN1GRIN2B | |
| SCHEMBL4059431 | 0.80 | ADORA1 (0.50) | ADORA1USP30ADORA3ADORA2AADORA2B | |
| SCHEMBL4055961 | 0.80 | GRIN1 (0.46) | GRIN1GRIN2B | |
| SCHEMBL4058461 | 0.76 | SCN2A (0.56) | ADORA1GRIN1GRIN2BMAPK13MAPK9 | |
| SCHEMBL4051508 | 0.76 | USP30 (0.47) | ADORA1USP30ADORA3ADORA2AADORA2B | |
| SCHEMBL4061915 | 0.75 | USP30 (0.46) | ADORA1USP30ADORA3ADORA2AADORA2B | |
| SCHEMBL4057030 | 0.74 | SCN2A (0.53) | ADORA1MAPK13MAPK9MAPK12MAPK11 | |
| SCHEMBL4054509 | 0.74 | USP30 (0.47) | ADORA1USP30ADORA3ADORA2AADORA2B | |
| SCHEMBL4063852 | 0.74 | USP30 (0.70) | USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622479-B2 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20050101647-A1 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1460067-A1 | BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101647-A1 | Bicyclic derivative, its production and use | ABL1, SRC, PTK2B | ADORA1 3592/4885USP30 2997/4885GRIN1 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.